HIGHLIGHTS
SUMMARY
Although novel therapies including targeted therapy and immune therapy are implemented in clinical practice and clinical trial design (Keenan and Tolaney, 2020; Vagia et_al, 2020; Bianchini et_al, 2022; Tarantino et_al, 2022), clinical outcomes for TNBC remain unsatisfactory. From a previous study, the authors collected the gene sets for the evaluation of immune-related characteristics including different types of human immune cell subtypes and immune-related activities (Charoentong et_al, 2017; Ru et_al, 2019). The authors used a time-dependent receiver operating characteristic (ROC) curve to assess the sensitivity and specificity of the URG signature by . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.